What are the new drugs for rheumatoid arthritis (RA)?
The newest drugs for the treatment of rheumatoid arthritis are the Janus kinase (JAK) inhibitors, which are FDA approved under the brand names Rinvoq, Olumiant, and Xeljanz.
Janus kinase (JAK) inhibitors work by blocking the activity of one or more of the Janus kinase enzymes (JAK1, JAK2, JAK3, TYK2) in the JAK-STAT signaling pathway, an intracellular pathway that plays a major role in the release of the pro-inflammatory cytokines that stimulate inflammation in rheumatoid arthritis.
Janus kinase (JAK) inhibitors are part of a wider group of drugs called DMARDs (Disease-Modifying Anti-Rheumatic Drugs). DMARDs work to slow the progression of joint damage in rheumatoid arthritis.
For more information on the treatment of rheumatoid arthritis, see Rheumatoid Arthritis: Symptoms, Diagnosis & Treatment Options
New Treatments for Rheumatoid Arthritis - Latest FDA Approvals
Drug | Drug Class | Administration | Company | FDA Approved for RA | RA Indication | Other Indications |
---|---|---|---|---|---|---|
upadacitinib (Rinvoq) | Janus kinase (JAK) inhibitor |
oral extended-release tablets once daily |
AbbVie Inc. | 16-Aug-2019 |
|
|
baricitinib (Olumiant) | Janus kinase (JAK) inhibitor | oral tablets once daily | Eli Lilly and Company | 31-May-2018 |
|
|
sarilumab (Kevzara) | interleukin-6 (IL-6) receptor antagonist |
subcutaneous injection every 2 weeks |
Sanofi and Regeneron | 22-May-2017 |
|
|
tofacitinib (Xeljanz XR) | Janus kinase (JAK) inhibitor | oral extended-release tablets once daily | Pfizer Inc. | 23-Feb-2016 |
|
|
golimumab (Simponi Aria) | tumor necrosis factor (TNF) blocker | intravenous infusion at weeks 0 and 4, then every 8 weeks | Janssen Biotech, Inc. | 18-Jul-2013 |
|
|
tofacitinib (Xeljanz) | Janus kinase (JAK) inhibitor | oral tablets twice daily | Pfizer Inc. | 6-Nov-2012 |
|
|
tocilizumab (Actemra) | interleukin-6 (IL-6) receptor antagonist |
intravenous infusion every 4 weeks subcutaneous injection every 2 weeks, then every week |
Genentech, Inc. | 8-Jan-2010 |
|
|
certolizumab pegol (Cimzia) | tumor necrosis factor (TNF) blocker | subcutaneous injection at weeks 0, 2, and 4, then every 2-4 weeks | UCB, Inc. | 13-May-2009 |
|
|
golimumab (Simponi) | tumor necrosis factor (TNF) blocker |
subcutaneous injection once a month |
Janssen Biotech, Inc. | 24-Apr-2009 |
|
|
rituximab (Rituxan) | CD20-directed cytolytic antibody | intravenous infusion two infusions separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation (not sooner than every 16 weeks) | Genentech, Inc. | 28-Feb-2006 |
|
|
abatacept (Orencia) | selective T cell costimulation modulator |
intravenous infusion at 0, 2 and 4 weeks, then every 4 weeks subcutaneous injection once weekly |
Bristol-Myers Squibb Company | 23-Dec-2005 |
|
|
adalimumab (Humira) | tumor necrosis factor (TNF) blocker |
subcutaneous injection every 2 weeks |
AbbVie Inc. | 31-Dec-2002 |
|
|
anakinra (Kineret) | interleukin-1 receptor antagonist |
subcutaneous injection once daily |
Swedish Orphan Biovitrum AB | 14-Nov-2001 |
|
|
infliximab (Remicade) | tumor necrosis factor (TNF) blocker | intravenous infusion at 0, 2, and 6 weeks, then every 8 weeks | Janssen Biotech, Inc. | 10-Nov-1999 |
|
|
etanercept (Enbrel) | tumor necrosis factor (TNF) blocker |
subcutaneous injection once weekly |
Immunex Corporation | 2-Nov-1998 |
|
|
leflunomide (Arava) | pyrimidine synthesis inhibitor | oral tablets once daily | sanofi-aventis U.S. LLC | 10-Sep-1998 |
|
|
The biosimilars for the tumor necrosis factor (TNF) blockers Humira, Remicade, and Enbrel are also FDA approved for the treatment of rheumatoid arthritis:
Related questions
- What are monoclonal antibodies?
- What are biosimilar drugs and how do they compare to biologics?
- Does Rituxan cause hair loss?
Humira (adalimumab) Biosimilars
- Amjevita (adalimumab-atto)
- Cyltezo (adalimumab-adbm)
- Hyrimoz (adalimumab-adaz)
- Hadlima (adalimumab-bwwd)
- Abrilada (adalimumab-afzb)
- Hulio (adalimumab-fkjp)
- Yusimry (adalimumab-aqvh)
- Idacio (adalimumab-aacf)
- Yuflyma (adalimumab-aaty)
Remicade (infliximab) Biosimilars
- Inflectra (infliximab-dyyb)
- Renflexis (infliximab-abda)
- Ixifi (infliximab-qbtx)
- Avsola (infliximab-axxq)
Enbrel (etanercept) Biosimilars
Read next
What is the success rate of Rituxan (rituximab) in patients with blood cancers?
In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).
Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.
Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading
What is the success rate of Rituxan (rituximab) in rheumatoid arthritis?
Treatment with Rituxan (rituximab) successfully improves patient outcomes in patients with rheumatoid arthritis including reducing symptoms, reducing levels of fatigue and disability, and increasing health-related quality of life. It also slows the progression of structural damage in joints. Continue reading
What is Actemra used to treat?
Actemra is used to treat several different conditions that have inflammation as a common characteristic, such as Rheumatoid arthritis (RA), Giant Cell Arteritis (GCA), Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), Polyarticular Juvenile Idiopathic arthritis (PJIA), Systemic Juvenile Idiopathic arthritis (SJIA), Cytokine Release Syndrome (CRS), and COVID-19.
Continue readingRelated medical questions
- How will I feel after a Rituxan infusion?
- How long does it take for Rituxan to work?
- What biosimilars have been approved in the United States?
- What are biologic drugs and how do they work?
- How does the drug Rituxan work?
- What is the difference between Truxima and Rituxan?
- How do you prepare for a Rituxan infusion?
- Are lung nodules common after Bendeka & Rituxan therapy?
- What is the difference between Rituxan and Rituxan Hycela?
- What should I tell my healthcare provider before receiving Actemra?
- What is the effect of Actemra on patients with COVID-19?
- Is tocilizumab (Actemra) effective for treating COVID-19?
- How long does Cimzia take to work?
- What's the difference between Cimzia and Humira?
- How and where is the Cimzia injection given?
- Does Cimzia cause hair loss?
- Can Cimzia cause skin problems?
- What is the mechanism of action for Cimzia?
- Does Cimzia (certolizumab) make you gain weight?
Related support groups
- Rituxan (21 questions, 103 members)
- Actemra (14 questions, 53 members)
- Rituximab (12 questions, 53 members)
- Cimzia (9 questions, 44 members)
- Humira (69 questions, 369 members)
- Enbrel (25 questions, 209 members)
- Remicade (23 questions, 185 members)
- Xeljanz (21 questions, 37 members)
- Adalimumab (14 questions, 14 members)
- Etanercept (13 questions, 12 members)
- Amjevita (8 questions, 5 members)